Business Description
PharmaNutra SpA
ISIN : IT0005274094
Compare
Compare
Traded in other countries / regions
PHN.Italy761.GermanyPHNm.UK IPO Date
2021-01-04Description
PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, Asia, and others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.42 | |||||
| Debt-to-EBITDA | 0.79 | |||||
| Interest Coverage | 24.5 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 7.89 | |||||
| Beneish M-Score | -2.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 20.2 | |||||
| 3-Year EBITDA Growth Rate | 19.2 | |||||
| 3-Year EPS without NRI Growth Rate | -3.3 | |||||
| 3-Year Book Growth Rate | 13.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 24.73 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 13.01 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.66 | |||||
| 9-Day RSI | 33.68 | |||||
| 14-Day RSI | 40 | |||||
| 3-1 Month Momentum % | -4.55 | |||||
| 6-1 Month Momentum % | 20.81 | |||||
| 12-1 Month Momentum % | 2.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.26 | |||||
| Quick Ratio | 1.98 | |||||
| Cash Ratio | 0.87 | |||||
| Days Inventory | 39.42 | |||||
| Days Sales Outstanding | 74.23 | |||||
| Days Payable | 72.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.59 | |||||
| Dividend Payout Ratio | 0.51 | |||||
| 3-Year Dividend Growth Rate | 20.3 | |||||
| Forward Dividend Yield % | 1.59 | |||||
| 5-Year Yield-on-Cost % | 3.93 | |||||
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | 0.43 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 35.31 | |||||
| Operating Margin % | 23.5 | |||||
| Net Margin % | 14.29 | |||||
| FCF Margin % | 17.06 | |||||
| ROE % | 29.43 | |||||
| ROA % | 14.46 | |||||
| ROIC % | 23.07 | |||||
| 3-Year ROIIC % | -3.07 | |||||
| ROC (Joel Greenblatt) % | 70.6 | |||||
| ROCE % | 32.46 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 32.4 | |||||
| Forward PE Ratio | 24.34 | |||||
| PE Ratio without NRI | 32.61 | |||||
| Price-to-Owner-Earnings | 47.99 | |||||
| PEG Ratio | 1.79 | |||||
| PS Ratio | 4.64 | |||||
| PB Ratio | 8.89 | |||||
| Price-to-Tangible-Book | 14.59 | |||||
| Price-to-Free-Cash-Flow | 27.1 | |||||
| Price-to-Operating-Cash-Flow | 23.02 | |||||
| EV-to-EBIT | 18.8 | |||||
| EV-to-EBITDA | 16.6 | |||||
| EV-to-Revenue | 4.54 | |||||
| EV-to-FCF | 27.21 | |||||
| Price-to-GF-Value | 0.7 | |||||
| Price-to-Projected-FCF | 5.83 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.29 | |||||
| Price-to-Graham-Number | 4.56 | |||||
| Price-to-Net-Current-Asset-Value | 76.29 | |||||
| Earnings Yield (Greenblatt) % | 5.32 | |||||
| FCF Yield % | 3.77 | |||||
| Forward Rate of Return (Yacktman) % | 20.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PharmaNutra SpA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 113.831 | ||
| EPS (TTM) (€) | 1.682 | ||
| Beta | 0.3 | ||
| 3-Year Sharpe Ratio | -0.33 | ||
| 3-Year Sortino Ratio | -0.48 | ||
| Volatility % | 26.37 | ||
| 14-Day RSI | 40 | ||
| 14-Day ATR (€) | 0.762811 | ||
| 20-Day SMA (€) | 54.535 | ||
| 12-1 Month Momentum % | 2.91 | ||
| 52-Week Range (€) | 45 - 63.1 | ||
| Shares Outstanding (Mil) | 9.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PharmaNutra SpA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PharmaNutra SpA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
PharmaNutra SpA Frequently Asked Questions
What is PharmaNutra SpA(FRA:761)'s stock price today?
The current price of FRA:761 is €53.40. The 52 week high of FRA:761 is €63.10 and 52 week low is €45.00.
When is next earnings date of PharmaNutra SpA(FRA:761)?
The next earnings date of PharmaNutra SpA(FRA:761) is .
Does PharmaNutra SpA(FRA:761) pay dividends? If so, how much?
The Dividend Yield %  of PharmaNutra SpA(FRA:761) is 1.59% (As of Today), Highest Dividend Payout Ratio of PharmaNutra SpA(FRA:761) was 0.6. The lowest was 0.31. And the median was 0.46. The  Forward Dividend Yield % of PharmaNutra SpA(FRA:761) is 1.59%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers